ClinicalTrials.gg

Program

BL1332

A development code. Also written as “Topical Ocular BL1332 low dose”, “Topical Ocular BL1332 high dose” and “BL1332 eye drops”.

Its studies are mostly in Pain, Postoperative · Eye Pain, led by Bausch Health Companies.

Furthest: phase 2, since Jan 26, 20263 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies31 open or runningphase 2since Jan 26, 2026May 8, 2025Nov 2026phase 1 · NCT06978244

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 8, 2025First study: phase 1 study in Eye PainFirst studyNCT06978244 · 24 enrolled · United States
  2. Jan 26, 2026Phase 2 study in Pain, PostoperativePhase 2 reachedNCT07412496 · 130 enrolled · United States
  3. Jul 16, 2026Phase 1 study in HealthyNCT07717918 · 28 enrolled · United States

Ahead

  1. Nov 2026Primary completion: phase 1 study in Eye PainNCT06978244

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07717918Healthy · United States1CompletedAug 5, 202628
NCT07412496Pain, Postoperative · United States2CompletedOct 4, 2026130
NCT06978244Eye Pain · United States1Active, not recruitingNov 202624

How it is read

Names in the registry

  • “Topical Ocular BL1332 low dose”, 1 entry
  • “Topical Ocular BL1332 high dose”, 1 entry
  • “BL1332 eye drops”, 1 entry
  • “BL1332 ophthalmic solution”, 1 entry

Codes read as this program: BL1332.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
BL1332 (Bausch Health Companies): development program | ClinicalTrials.gg